Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
34
Participants
Timeline
Start Date
September 30, 2013
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL
FURESTEM-AD Inj.
Trial Locations (1)
137-701
Catholic Medical Center, Seoul
All Listed Sponsors
lead
Kang Stem Biotech Co., Ltd.
INDUSTRY
NCT01927705 - Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) | Biotech Hunter | Biotech Hunter